Loading…
← CockpitCompetitor Analysis › OBCK.DE Ottobock SE & Co. KGaAOpen in the cockpit ↗

Ottobock SE & Co. KGaAOBCK.DECompetitor analysis, valuation and peers

Germany · EUR·Health Care›Medical Specialties

German maker of prosthetic limbs, orthotic braces and wheelchairs that help people with disabilities and mobility limitations.

≈ A German Hanger Inc./Invacare for prosthetics and mobility devicesMomentum laggard 4
Mkt cap
$2.65B
US dollars, full cap
Free float
14%
of shares outstanding
$/day
$3.18M
20-day average traded
Fwd P/E
12.3×
forward earnings
ROIC−WACC
+7.1 pp
WACC 6.4%
Hurdle
-9 pp
Req g minus delivered
Next earnings
90 days
16 Feb 2027
Close · EUR€37.75
1D-1.6%
1W-19.7%
1M-26.1%
3M-36.8%
6M-30.4%
YTD-42.1%
1Y-48.8%
ATR %5.2%
52w lowhigh50.6% off high

What Ottobock SE & Co. KGaA does

German maker of prosthetic limbs, orthotic braces and wheelchairs that help people with disabilities and mobility limitations.

Largely paid by health insurers, which reimburse the fitting of prosthetic limbs and braces, so rules and approval times matter. It makes the devices for sale to independent orthopedic workshops and also runs its own patient-care clinics, earning fitting and service fees there. The Naeder family, which has owned it for generations, keeps control.

In one line: A German Hanger Inc./Invacare for prosthetics and mobility devices.

Products and services

  • Prosthetic limbs (bionic/myoelectric)
  • Orthotic braces/supports
  • Wheelchairs/mobility devices
  • Patient care/rehab equipment

Customers

  • Amputees/patients (via orthopedic technicians)
  • Hospitals/rehab clinics
  • Healthcare payers/insurers

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Prosthetics, orthotics & mobility…

What could go right

  • Aging population/diabetes-driven amputation demand
  • Bionic technology adoption

What could go wrong

  • Insurance reimbursement constraints
  • High R&D cost for advanced prosthetics

Moat: narrow (brand, IP / patents, distribution). Leading global brand in advanced prosthetics with strong clinician relationships, but faces reimbursement-dependent demand.

Headquarters: Duderstadt, Germany · Founded: 1919 · Employees: 10,365

Named competitors

  • Ossur private or unlisted
  • Invacare (restructured) private or unlisted
  • Hanger (private, acquired) private or unlisted

Ottobock SE & Co. KGaA at a glance

Size Ottobock SE & Co. KGaA (OBCK.DE) is a Germany Health Care company (Medical Specialties) with a market value of $2.65B, the 91st largest of 198 Germany companies the cockpit tracks. Shares closed at €37.75 on 18 Nov 2026.

Performance Over six months the shares fell 30.4%, against -2.2% for the median peer and -0.9% for the Germany market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 4.7% over the last twelve months (peer median +3.1%); the operating margin is 16.7% (peer median 7.4%).

Valuation It trades at 12.3× forward earnings against a peer median of 24.4× (2nd cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -9 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.1 points above its cost of capital (6.4% WACC).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 100OBCK.DE 70
Six months, rebased to 100: Ottobock SE & Co. KGaA against the median of its 20 peers (local-currency closes).

Ottobock SE & Co. KGaA financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€1.77B€1.68B€1.60B€1.50B€1.33B
Revenue growth—+5%+7%+12%—
Gross profit€939M€886M€812M€702M€597M
EBITDA€450M€372M€300M€204M€143M
Net income€150M€90.2M€30.2M€49.0M€76.4M
Free cash flow€159M€176M€112M€57.7M-€40.5M
Capital expenditure€102M€109M€102M€89.4M€114M
Total debt€1.18B€1.05B€1.20B€1.19B€1.19B

Quarterly statements and history in the cockpit →

Ottobock SE & Co. KGaA competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-20%0%+20%CELCCOTNEBOATRCMOVE002901NEOG300529EKTA-B6880296881142276AFXIRTC300003METN603301DRW86883016951OBCK.DE6-month return →1-month return →
Up and to the right = strong over both horizons. Ottobock SE & Co. KGaA is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×100×200×COTNEBOATRCMOVE002901300529EKTA-BAFXIRTCMETN603301DRW86883016951OBCK.DERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ottobock SE & Co. KGaA is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%EBOATRC002901300529EKTA-B6880296881142276IRTC300003603301DRW86951OBCK.DEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ottobock SE & Co. KGaA is the large dot.

Ottobock SE & Co. KGaA competitors and peer comparison

How Ottobock SE & Co. KGaA compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ottobock SE & Co. KGaA against its 20 peers (data as of 18 Nov 2026)
MeasureOBCK.DEPeer medianRank in peer set
1-month return-26.1%-3.0%lowest of 21
6-month return-30.4%-2.2%2nd lowest of 21
Distance from 52-week high-50.6%-28.4%4th lowest of 21
Revenue growth (TTM)+4.7%+3.1%10th highest of 20
Operating margin16.7%7.4%6th highest of 20
Forward P/E12.3×24.4×2nd cheapest of 19
Growth the price implies (Req g, 7 yrs)-1.2%11.3%2nd least demanding of 15
Growth delivered (Del g)+8.0%+8.5%8th highest of 15
Hurdle (Req g minus delivered)-9.2 pp+6.1 pp3rd least demanding of 15
ROIC minus cost of capital+7.1 pp-0.7 pp5th highest of 20
EV / EBITDA7.8×17.1×2nd cheapest of 11
Net debt / EBITDA2.4×1.5×4th most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%12.3×-1.2%+8.0%
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a
EBOS EBO.AXAustralia$2.50B+7%+3%3%15.7×4.7%+6.8%
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
Medacta MOVE.SWSwitzerland$2.48B-28%+8%15%24.0×n/an/a
Double Medical Technology 002901.SZChina$2.43B-2%+13%26%24.2×7.6%+10.4%
Neogen NEOGUnited States$2.42B+25%0%0%32.6×n/an/a
Jafron Biomedical 300529.SZChina$2.35B+3%+1%37%24.3×6.1%+0.6%
Elekta EKTA-B.STSweden$2.35B0%-7%6%15.3×10.7%+4.0%
Micro-Tech (Nanjing) 688029.SSChina$2.33B0%+6%18%28.1×11.9%+19.2%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
Shanghai Conant Optical 2276.HKHong Kong$2.25B-17%+8%29%22.1×-1.1%+14.1%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%
Metall Zug METN.SWSwitzerland$2.19B+20%0%-10%139.8×n/an/a
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
Draegerwerk AG & Co. KGaA DRW8.DEGermany$2.13B+25%+5%7%10.2×-10.2%+0.4%
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
JEOL 6951.TJapan$2.12B-2%-15%12%15.5×22.2%+10.2%

Questions

Who are Ottobock SE & Co. KGaA's main competitors?
Named competitors: Ossur (private or unlisted), Invacare (restructured) (private or unlisted), Hanger (private, acquired) (private or unlisted). The cockpit's measured peer set (industry) also includes Celcuity (CELC), COMET (COTN.SW), EBOS (EBO.AX), AtriCure (ATRC), Medacta (MOVE.SW), Double Medical Technology (002901.SZ).
Is Ottobock SE & Co. KGaA expensive compared with its peers?
On forward p/e it trades at 12.3× against a peer median of 24.4×, 2nd cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -9 pp: the price already allows for a slowdown.
How has Ottobock SE & Co. KGaA stock performed?
Over six months to 18 Nov 2026 the shares returned -30.4% against -2.2% for the median peer; over one year -48.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.